J&J Financial News

(Reuters) — The U.S. health regulator said on Monday companies will be required to add a serious warning on the prescribing information for cancer therapies known as CAR-T, made by Gilead Sciences (NASDAQ:GILD), Johnson & Johnson (NYSE:JNJ), Novartis and others.

Quiver Quantitative — The biotechnology sector, known for its high-risk, high-reward investment landscape, has once again proven its potential for delivering staggering returns. The recent acquisition of Ambrx Biopharma by Johnson & Johnson (JNJ) serves as a prime example. J&J's offer to purchase Ambrx at $28 per share represents a significant premium over its previous closing price, effectively valuing the company at an impressive $2 billion. This deal is particularly noteworthy for Ambrx's shareholders, who saw the stock languishing at a mere 41 cents per share in December 2022, a low that had put the company at risk of delisting.

Pee Safe, a hygiene and wellness brand, said only less than a third of women in India use or have access to female and intimate hygiene products such as sanitary pads, tampons, menstrual cups and vaginal wash among other period related products, indicating the potential market as well as the need to raise awareness about such products. With feminine hygiene penetration lower than 30% in India, a host of companies have entered the segment historically dominated by P&G and J&J. While they have a significant presence in India, the challenges are also equally massive in increasing market penetration due to limited awareness about feminine hygiene and low purchasing power of a significant portion of the Indian women populace.

By Jonathan Stempel

By Patrick Wingrove and Bhanvi Satija

Five days, Tom Barklage knew, was not enough time to recover from the death of his son.

Write to Peter Loftus at [email protected] Alert!Livemint tops charts as the fastest growing news website in the world

In a series of moves experts say signal a shift in how developing countries deal with pharmaceuticals, South Africa, Colombia and others have recently adopted a more combative approach towards drugmakers, pushing back on policies that deny treatment to...

(Reuters) -GSK will pay about $1 billion for exclusive rights to further develop and commercialize Johnson & Johnson (NYSE:JNJ)'s hepatitis B therapy, the British drugmaker said on Tuesday.

(Reuters) -Johnson & Johnson disclosed on Friday that the U.S. Department of Justice (DOJ) in July had sought documents and information related to the drugmaker's free and discounted eye surgery products in connection with a civil investigation.

J&J has talc cases set for trial everywhere from Pennsylvania to California between November and December 2024, some of which involve consolidated claims by more than a half-dozen plaintiffs, according to their lawyers. Those trials were scheduled after a judge in July threw out a J&J unit’s latest Chapter 11 case aimed at resolving all current and future talc claims. Since 2016, J&J has been hit with at least $570 million in damage awards over talc-related cancer claims and paid out at least $2.5 billion in settlements, according to data compiled by Bloomberg. “With all those trials staring them in the face, of course they want their unit to run back into bankruptcy,” said Carl Tobias, a University of Richmond professor who teaches about mass torts and has followed the talc cases.

(Reuters) -Johnson & Johnson on Tuesday raised its 2023 profit forecast, helped by resilient demand for its anti-inflammatory drug Stelara and recorded a $21 billion gain from the spin off of its consumer health unit.

(Reuters) — A New Jersey appeals court on Tuesday threw out a $223.8 million verdict against Johnson & Johnson (NYSE:JNJ) in a trial over four plaintiffs' claims that they developed cancer from being exposed to the company's talc powder products.

anti-TB drug Bedaquiline to other countries without the fear of litigation, with multinational pharma giant Johnson & Johnson (J&J) confirming that it will not enforce secondary patents for Bedaquiline in any of the low and middle income countries. «The decision is intended to assure current and future generic manufacturers that they may manufacture and sell high quality generic versions of SIRTURO without a concern that the Company will enforce its bedaquiline patents, provided the generic versions of SIRTURO® produced or supplied by generic manufacturers are of good quality, medically acceptable, and are used only in the 134 low- and middle-income countries,» J&J said in a statement last week.

Advent International on Friday announced the completion of its majority acquisition of Hyderabad-based listed contract development and manufacturing organisation (CDMO) Suven Pharma. Advent acquired 50.1% stake in Suven at an agreed price of Rs 495/share in December last year a firm promoted Venkat Jasti and his family members for Rs 6,313 crore paying ₹495 per share.

GENEVA (Reuters) -Global health aid agency Unitaid has written to Johnson & Johnson (NYSE:JNJ)'s (J&J) CEO Joaquin Duato, urging «immediate action» to expand access to the company's tuberculosis drug bedaquiline, which is protected by patents hindering generic alternatives.

A multiple myeloma diagnosis can be devastating. Encouragingly, though, the market is getting increasingly crowded with powerful new therapies that can extend patients’ lives. Cell therapy is one particular area of great hope, with clinical data from Johnson & Johnson’s Carvykti driving excitement in the medical field and on Wall Street.

U.S.-based pharmaceuticals company Johnson & Johnson is being investigated in South Africa for allegedly charging “excessive” prices for a key tuberculosis drug

By Jonathan Stempel

health care giant, Thursday said it has replaced its 130 years well-known script logo with a modern look that reflects its sharpened focus on pharmaceuticals and medical devices. The original script used since 1887— based on co-founder James Wood Johnson's signature — will still be seen for now on consumer products like baby shampoo from Kenvue, a new company recently spun off from J&J. The signature logo was “one of the longest-used company emblems in the world," J&J declared in a 2017 website post.

Johnson & Johnson is signing off on a new logo, more than 130 years after creating the old one